COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY

被引：0
|
作者：
Taylor, D. C. [1 ]
Ozer-Deniz, S. [1 ]
Hill, G. [1 ]
Skornicki, M. [1 ]
Danel, A. [2 ]
Kunz, E. [3 ]
机构：
[1] I3 Innovus, Medford, MA USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen Europe GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71963-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A264
页数：2
相关论文
共 50 条
  • [1] CLINICAL CONSEQUENCES OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY
    Ozer-Deniz, S.
    Taylor, D. C.
    Hill, G.
    Skornicki, M.
    Danel, A.
    Kunz, E.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
  • [2] Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients
    Lathia, Nina
    Isogai, Pierre K.
    De Angelis, Carlo
    Smith, Thomas J.
    Cheung, Matthew
    Mittmann, Nicole
    Hoch, Jeffrey S.
    Walker, Scott
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (15): : 1078 - 1085
  • [3] COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VS LIPEGFILGRASTIM TO REDUCE THE INCIDENCE OF FEBRILE NEUTROPENIA IN PATIENTS WITH EARLY STAGE BREAST CANCER OR NON-HODGKIN LYMPHOMA
    Fust, K.
    Li, X.
    Maschio, M.
    Villa, G.
    Parthan, A.
    Barron, R.
    Weinstein, M. C.
    Somers, L.
    Hoefkens, C.
    Lyman, G. H.
    VALUE IN HEALTH, 2015, 18 (03) : A204 - A204
  • [4] Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany
    Sehouli, J.
    Goertz, A.
    Steinle, T.
    Dubois, R.
    Plesnila-Frank, C.
    Lalla, A.
    von Minckwitz, G.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (09) : 385 - 389
  • [5] Cost-effectiveness of primary prophylaxis with pegfilgrastim versus filgrastim in non-hodgkin's lymphoma patients receiving CHOP-21.
    Kim, John
    Malin, Jennifer L.
    Doan, Quan V.
    Liu, Zhimei
    Dubois, Robert W.
    Lyman, Gary H.
    BLOOD, 2007, 110 (11) : 374B - 374B
  • [6] COST-EFFECTIVENESS OF PRIMARY PEGFILGRASTIM PROPHYLAXIS IN BREAST CANCER PATIENTS AT RISK OF FEBRILE NEUTROPENIA
    Aarts, M. J.
    Grutters, J. P.
    Peters, F. P.
    Mandigers, C. M.
    Dercksen, M. W.
    Stouthard, J. M.
    Nortier, J. W.
    van Laarhoven, H. W.
    van Warmerdam, L. J.
    Tjan-Heijnen, V. C.
    ANNALS OF ONCOLOGY, 2012, 23 : 501 - 501
  • [7] Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients
    Danova, Marco
    Chiroli, Silvia
    Rosti, Giovanni
    Doan, Quan V.
    TUMORI JOURNAL, 2009, 95 (02): : 219 - 226
  • [8] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Gebremariam, Girma Tekle
    Fentie, Atalay Mulu
    Beyene, Kebede
    Sander, Beate
    Gebretekle, Gebremedhin Beedemariam
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [9] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Girma Tekle Gebremariam
    Atalay Mulu Fentie
    Kebede Beyene
    Beate Sander
    Gebremedhin Beedemariam Gebretekle
    BMC Health Services Research, 22
  • [10] Cost effectiveness of pegfilgrastim vs filgrastim for febrile neutropenia(FN) prevention in breast cancer patients
    Danova, M.
    Rosti, G.
    Dubois, R. W.
    Chiroli, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 38 - 38
12345